Background--Elevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.
levated serum fibrinogen level is associated with major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) for patients with both elective and urgent indications. [1] [2] [3] Aside from being an acute phase reactant of inflammation, fibrinogen has crucial mechanistic roles in platelet crosslinking, platelet aggregation, and thrombus formation. 4 Previously, it has been identified as a risk factor for both short-and long-term adverse cardiovascular events. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] More recently, elevated baseline fibrinogen level has been reported to be associated with higher onthienopyridine platelet reactivity, periprocedural myocardial infarction (MI), and combined MACE within 12 months of the index PCI. [1] [2] [3] 15 The present study was performed to determine whether a longer term adverse relationship between baseline serum fibrinogen level, on-thienopyridine platelet reactivity, and ischemic cardiovascular events exists in patients undergoing PCI for both elective or acute coronary syndrome (ACS) indications.
Methods Patient Selection
The study was approved by the Institutional Review Board of the University of California, San Diego and the requirement for informed written consent was waived. Data from patients with coronary artery disease who underwent successful PCI with stenting or balloon angioplasty alone and measurement of serum fibrinogen within 24 hours of PCI were retrospectively gathered from a PCI database and electronic medical record. All subjects had been pretreated with a thienopyridine for ≥7 days before PCI or received a loading dose of clopidogrel 600 mg or prasugrel 60 mg at least 2 hours before PCI. Those with ST-segmentelevation MI within 72 hours before recruitment, age <18 years, or use of intravenous glycoprotein IIb/IIIa inhibitor within 30 days before index PCI were excluded.
Measurements
Baseline subject characteristics, history of cardiovascular disease and comorbidities, serum laboratory measurements, procedural details, postprocedure cardiac marker levels, and 2-year MACE were recorded. Baseline serum laboratory measurements included complete blood count, creatinine, complete lipid panel, C-reactive protein, fibrinogen, and cardiac markers of ischemic injury (creatine kinase-myocardial band, troponin I and/or troponin T) and were performed at the University of California, San Diego Medical Center. Cardiac markers of ischemic injury were measured every 6 to 8 hours following PCI until hospital discharge or up to 24 hours. Platelet function testing was performed during PCI using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA) with on-treatment platelet reactivity reported as "result" P2Y12 reaction units (PRU) and maximal platelet activation using high-concentration thrombin receptor-activating protein reported as "base" PRU. Platelet inhibition or percent change in result PRU from baseline (calculated as [1À(result PRU)/ (base PRU)]9100%) 16 was also reported as available. MACE included periprocedural MI (<24 hours after PCI: creatine kinase-myocardial band elevation at least 3-fold greater than the 99% upper limit of normal with normal baseline, or >20% rise from stable elevated baseline), 17 nonperiprocedural MI (>24 hours after PCI) with or without concurrent ST-segment elevation, rehospitalization for a suspected ACS, unplanned repeat revascularization, definite stent thrombosis, transient ischemic attack, ischemic or hemorrhagic stroke, or any death.
Statistical Analysis
The study was performed using a nested case-control design and powered to detect a 52 mg/dL difference in mean fibrinogen level between outcome groups (361 mg/dL versus 309 mg/dL, overall SD 109 mg/dL) at 6 months, using a 0.05 and power 0.8. This analysis revealed that at least 69 outcome events were needed. 1 Collection of study data from eligible subjects was continued until 69 MACE events were recorded at 6 months, then enrollees had both 6-month and 2-year MACE events identified. • This study uniquely identifies baseline serum fibrinogen as a significant, independent risk factor for late major adverse cardiovascular events after percutaneous coronary intervention (PCI).
• The association between baseline fibrinogen level and cardiovascular events in the post-PCI context and extending to 2-year follow-up after index PCI are novel study contributions.
• Additional analyses uniquely highlight the independent association between serum fibrinogen and 1) objective, clinically relevant ischemic cardiovascular events, and 2) nonacute events occurring >24 hours after PCI.
What Are the Clinical Implications?
• Incorporation of fibrinogen level measurement may strengthen the ability of ischemic risk prediction strategies to identify individuals at higher risk of late major adverse cardiovascular events occurring 12 to 24 months after PCI.
• Individuals with elevated fibrinogen could potentially benefit from prolonged dual-antiplatelet therapy extended beyond 12 months after index PCI or potentially oral direct thrombin inhibitors.
bare-metal stent [BMS]) in each patient, though a small minority underwent balloon angioplasty alone (4.8%). Two-year MACE after PCI occurred in 123 subjects (total events 35.8%: periprocedural MI alone 9.0%, rehospitalization for suspected ACS 6.3%, urgent revascularization 12.7%, non-ST-segment-elevation MI or ST-segment-elevation MI 4.5%, definite stent thrombosis 0.9%, transient ischemic attack or stroke 1.8%, all death 0.6%). Baseline subject characteristics, cardiac risk factors, comorbidities, and pharmacotherapy were compared between those with and without MACE ( (Figure 1) . A post hoc analysis comparing these 5 factors and 2-year MACE excluding rehospitalization for ACS was performed, which showed persistent relationships for fibrinogen level ≥280 mg/dL (P=0.004), ACS indication (P<0.001), TSL ≥32 mm (P<0.001), and use of a BMS (P=0.001). This analysis was repeated excluding both rehospitalization for ACS and revascularization (without an inciting MI) from 2-year MACE, which demonstrated significant relationships between fibrinogen level ≥280 mg/dL (P=0.018), ACS indication (P=0.002), TSL ≥32 mm (P=0.002), and use of a BMS (P=0.001) with unequivocal adverse events (non-STsegment-elevation MI /ST-segment-elevation MI, stent thrombosis, stroke/transient ischemic attack, and all-cause death).
Kaplan-Meier curve analysis showed increased 2-year MACE among those with fibrinogen ≥280 mg/dL (42.6% versus 22.0%, log-rank P<0.001) (Figure 2 ). More specifically, fibrinogen ≥280 mg/dL was associated with increased MACE among those undergoing PCI for either elective indications (35.4% versus 17.9%, log-rank P=0.005) or for an ACS (62.7% versus 36.0%, log-rank P=0.023) (Figure 3) . A landmark survival analysis at 24 hours (excluding periprocedural MI occurring <24 hours after PCI) showed significantly greater 2-year MACE in those with elevated fibrinogen (37.0% versus 18.3%, log-rank P<0.001) (Figure 4 ). The combined presence of any of the identified risk factors above was associated with a stepwise increase in MACE (0, 1, 2, 3, to 4 total risk factors: 8.3% versus 18.6% versus 31.2% versus 54.9% versus 84.6% 2-year MACE, log-rank P<0.001) ( Figure 5 ).
Discussion
The current study demonstrates that higher baseline fibrinogen is an independent predictor of 2-year MACE after elective or urgent PCI, and is driven by objective, clinically relevant ischemic cardiovascular events, independent of periprocedural MI. Additionally, index PCI for an ACS, longer total implanted stent length, use of BMS, and use of small-caliber stents are also independent predictors of 2-year MACE, while measures of platelet reactivity using the VerifyNow P2Y12 assay are not. Post hoc analyses using objective, clinically relevant definitions of ischemic events as well as a 24-hour landmark provide insight into the relation between baseline fibrinogen level and post-PCI MACE beyond prior reports at 6 and 12 months of follow-up. Kaplan-Meier survival curves, based on the fibrinogen cutoff of 280 mg/dL, show early and persistent separation during 2-year follow-up after index PCI. A 24-hour landmark analysis demonstrates that this relation persists after excluding periprocedural MI. In fact, subjects with elevated baseline fibrinogen (≥280 mg/dL) had higher incidence of subsequent ACS hospitalization, revascularization, MI, definite stent thrombosis, stroke, or death beyond 24 hours after PCI. This relation between elevated fibrinogen and 2-year MACE also persisted when limiting the analysis to only include acute MI, stent thrombosis, stroke, and death in the 2-year end point (excluding both ACS rehospitalization and revascularization without an inciting MI). These findings highlight the potential role for elevated baseline fibrinogen level to identify those at higher risk of future ischemic events that are both of high clinical relevance and occurring relatively late (12-24 months after index PCI). The presence of other clinically relevant factors including ACS presentation, greater total stent length, use of BMS, and use of small-caliber stents were independently associated with 2-year MACE and suggested roles for baseline disease burden and procedural details on subsequent events regardless of fibrinogen level. In particular, the use of BMS may represent the use of smallest-diameter stents (2.0 mm) or presence of comorbidities warranting shorter dual antiplatelet therapy duration. Total stent length difference between groups was also clinically relevant, representing greater underlying disease burden requiring multiple stents and more complex PCI procedures in those with subsequent MACE. The presence of multiple factors together with elevated fibrinogen level was associated with the greatest 2-year risk of MACE. An analysis of the GRAVITAS (Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety) Trial also identified multiple significant covariates, notably ACS presentation and TSL, in predicting 6-month combined death, MI, and stent thrombosis after PCI for stable coronary artery disease or ACS. 18 A post hoc analysis of the Dual Antiplatelet Therapy Study also identified multiple factors predicting late ischemic events, including MI at time of PCI and use of smaller-diameter stents, similar to the current study. However, the ability of these factors to predict late ischemic events 12 to 30 months after PCI remained limited with a c-statistic of 0.64 within a validation cohort. 19 Elevated serum fibrinogen was not measured in these previous studies and has been identified by the current study to be a unique independent predictor of MACE up to 2 years after PCI. Furthermore, the current study highlights how elevated fibrinogen level augments the association of ACS presentation, longer total stent length, and small-diameter stent with 2-year MACE. Integrating serum fibrinogen level may help improve the performance of this late ischemia prediction model as well. If validated, serum fibrinogen could play a role in determining which patients could benefit from prolonged dual-antiplatelet therapy extended beyond 12 months after index PCI or potentially direct thrombin inhibitors. Multiple mechanisms may explain the association between elevated fibrinogen level and long-term cardiovascular events in the current study population. Serum fibrinogen has a clear role in arterial thrombosis as a key component of platelet crosslinking and clot formation. 4 Serum fibrinogen is produced and released in response to systemic inflammation, which can be present in those with more extensive cardiovascular risk factors and coronary heart disease, and further manifested by acute clinical presentations. Platelet activation in these contexts can further contribute to release of intracellular fibrinogen stores, potentiate thrombus formation, and increase cardiovascular risk. The interplay between these mechanisms suggests a correlation between elevated fibrinogen level and increased cardiovascular events, but a direct causal link has not been established. Results of the current study showed that while elevated baseline fibrinogen level (≥280 mg/dL) is independently associated with 2-year MACE, it remains a nonspecific marker of events based on receiveroperator characteristic curve analysis (81.5% sensitivity, 39.0% specificity). We have previously reported that a higher fibrinogen level (≥345 mg/dL) was associated with periprocedural MI after PCI but also had limited specificity. 1 It is possible that a higher fibrinogen threshold predicts ischemic risk during PCI with administration of potent antiplatelet/ anticoagulant therapy while a lower threshold might be associated with longer-term MACE. Furthermore, these identified cutoffs are within the normal range of the fibrinogen assay (150-400 mg/dL) and call into question whether a different range of normal values needs to be ascertained to better discriminate risk for patients with cardiovascular Similar to the GRAVITAS Trial, results of the current study did not show a significant relationship between measures of platelet reactivity using the VerifyNow P2Y12 assay (including PRU and percent platelet inhibition values) and occurrence of MACE. The current study was specifically powered to detect a difference in fibrinogen level across outcome groups and may have been underpowered to also detect differences in platelet function measurements. Nevertheless, study results show that baseline fibrinogen level was more closely associated than platelet function with the occurrence of MACE at 2 years after PCI.
Limitations
This was a retrospective study and findings should be confirmed in a prospective manner. Post-PCI dual antiplatelet therapy and thienopyridine selection was determined at time of discharge after index procedure and may have been subsequently modified. Fibrinogen level was obtained at a single time point and variability in its level over time was not assessed. Platelet function test results were not available for all study subjects.
Conclusions
Elevated serum fibrinogen level (≥280 mg/dL) is independently associated with 2-year MACE after PCI, driven by objective, clinically relevant ischemic events. ACS indication for initial PCI, TSL ≥32 mm, use of stents ≤2.5 mm, and any BMS use during PCI are also independent predictors of 2-year MACE. The highest 2-year MACE is predicted by the presence of these factors together, while measures of on-thienopyridine platelet reactivity using the VerifyNow P2Y12 assay are not associated with 2-year MACE after PCI. . Kaplan-Meier curves show a stepwise increase in 2-y MACE (8.3% vs 18.6% vs 31.2%, vs 54.9% vs 84.6%, log-rank P<0.001) in the presence of none (blue) or any combination of 1 (green), 2 (orange), 3 (red), or 4 (purple) previously identified risk factors: ACS indication for PCI, fibrinogen ≥280 mg/dL, use of a bare-metal stent, use of a ≤2.5-mm diameter stent, and total stent length ≥32 mm. No subject had all 5 risk factors. ACS indicates acute coronary syndrome; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention.
